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I. Abstract 
Background: Obesity is a widespread health concern and established risk factor for 
basal-like breast cancer. However, studies are conflicted on the benefits of weight loss 
relevant to breast cancer prevention. Recent studies suggest that certain methods of 
robust weight loss with long-term maintenance, such as bariatric surgery, might in fact 
be able to reverse obesity-associated breast cancer risk. 
 
Hypothesis: We hypothesize that weight loss by sleeve gastrectomy will generate 
sufficient metabolic normalization to reverse obesity-driven mammary tumor burden 
more effectively than weight loss by diet alone. 
 
Methods: Mice were fed a low-fat control (CON) or high-fat diet-induced obesity (DIO) 
regimen for 15 weeks to model chronic obesity. DIO mice were randomized to continue 
on a high-fat diet (Obese) or undergo weight loss by either sleeve gastrectomy (~70% 
excision of the stomach) in combination with switching to a low-fat diet or by switching 
to a low-fat diet alone, resulting in formerly obese (FOB)-Surg and FOB-Diet mice, 
respectively. Additionally, a subset of normal weight (NW) Control mice (Con, n=25) 
was maintained on a low-fat diet throughout the study. NW Control, FOB-Diet, and 
Obese mice underwent a sham procedure to control for the insult of surgery. FOB-Surg 
and FOB-Diet mice did not lose a significantly different amount of weight and body fat; 
both groups had significantly lower weight and percent body fat than Obese mice. Eight 
weeks after surgical procedures and diet switches, all mice on study were orthotopically 
injected with E0771 mammary tumor cells, which model BLBC. 
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Results: At the end of study, ex vivo tumor volume in FOB-Surg mice was not 
significantly different from NW Control mice and significantly different from Obese mice. 
However, tumor volume in FOB-Diet mice was significantly different from NW Control 
mice and not significantly different from Obese mice. In addition, FOB-Surg mice had 
levels of serum tumor necrosis factor-alpha (TNF-a), insulin, and mammary adipocyte 
size that were not significantly different from NW Control mice and significantly different 
from FOB-Diet and Obese mice. Lastly, pathway analysis of mammary tissue gene 
expression revealed redundant upregulation of genes in extracellular matrix remodeling 
and growth factor signaling in Obese vs. FOB-Surg and FOB-Diet vs. FOB-Surg mice. 
 
Conclusions: Our results demonstrate that surgical weight loss imparted a plurality of 
metabolic advantages, functional genomic changes, and successful reversal of obesity-
associated mammary tumor burden that were not similarly achieved by dietary weight 
loss.  
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II. Introduction 
 The predominance of obesity persists in the United States, with recent 
epidemiologic studies reporting a prevalence of 37.7% in the adult population (1). A 
robust body of evidence demonstrates that obesity significantly increases the risk of 
developing breast cancer in postmenopausal women (2). Furthermore, obese women 
experience poorer breast cancer outcomes by virtue of increased tumor grade at clinical 
presentation, disease recurrence, and substandard response to certain therapies (3). 
Accordingly, rigorous scientific investigation has been dedicated to interrogating the 
mechanisms complicit in this obesity-cancer link. 
 Obesity is attendant to a spectrum of physiological aberrations resulting from 
chronic positive energy intake (4). In obesity, excess energy is converted to 
triacylglycerol and stored in various adipose tissue depots throughout the body. The 
obese state is thus associated with profound expansion of the adipose tissue, which 
occurs by adipocyte hyperplasia (increase in adipocyte number) or hypertrophy 
(increase in adipocyte size). In obese adults, hypertrophy predominates as the 
mechanism to support the growth in adipose tissue (5). Adipocyte hypertrophy, and the 
associated fatty acid spill over, results in insulin resistance, elevated serum 
triglycerides, local tissue hypoxia, inflammation, and altered sex hormone levels (6). In 
consequence, obesity is a strong risk factor for a host of diseases including 
cardiovascular disease, type II diabetes, and a variety of cancers including those of the 
breast, pancreas, colorectum, endometrium, esophagus, and kidney (7). 
 Several key obesity-driven physiological disruptions have been identified as 
critical mediators between host energy status and breast cancer risk. Namely, these 
	 7	
include growth factor signaling– particularly insulin-like growth factor 1 (IGF-1)– and 
inflammatory cytokines and adipokines secreted from immune cells and adipocytes (8). 
Obesity is known to induce insulin resistance, resulting in compensatory 
hyperinsulinemia, which causes enhanced synthesis of IGF-1. IGF-1 is a potent mitogen 
that activates a receptor-tyrosine kinase signaling cascade resulting in cell growth, 
survival, proliferation, and evasion of apoptosis; thus, IGF-1 and intracellular growth 
factor signaling are heavily implicated in breast cancer risk and progression (9). Obesity 
confers its pro-inflammatory effects in part as a result of adipose tissue remodeling. 
Positive energy balance and triglyceride storage causes adipocyte hypertrophy. In 
consequence, adipocytes can outgrow supporting vasculature, resulting in hypoxia, and 
expand the margins permitted by the outer cellular membrane, resulting in apoptosis 
(7). Moreover, it is well-documented that adipose tissue in obese subjects exhibits 
increased secretions of several pro-inflammatory cytokines, including interleukin-6 (IL-
6), tumor necrosis factor-a (TNF-a), and monocyte chemoattractant protein-1 (MCP-1) 
(7). These cellular phenomena contribute to substantial recruitment of immune cells to 
the adipose tissue as well as proliferation of macrophage populations native to adipose 
depots (6, 7). In this inflammatory milieu, activated macrophages supply significant 
secretions of cytokines and engage in phagocytosis of necrotic engorged adipocytes, 
forming visible histopathological signatures known as crown-like structures (CLS) (10). 
This cycle can self-perpetuate by way of cytokine-induced lipolysis, which results in 
release of fatty acids that activate toll-like receptors on immune cells to sustain elevated 
cytokine production (11). 
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 Tissues proximal to adipose tissue, such as the mammary epithelium, are 
vulnerable to this obesity-associated inflammatory cascade, which promotes 
carcinogenic events and cancer progression through several molecular levers. For 
instance, increased IL-6 secretions promote cell proliferation through the Janus Kinase 
(JAK)/ Signal transducer and activator of transcription 3 (STAT3) pathway (12), and 
TNF-a secretions promote cell proliferation, angiogenesis, and evasion of apoptosis via 
nuclear factor-kappa B (NF-kB) signaling (13). In addition, reactive oxygen and nitrogen 
species originating from adipose tissue macrophages jeopardize genomic integrity by 
inducing structural DNA alterations (7). Therefore, it is critical to target the progression 
of obesity-associated adipose dysregulation in order to reduce the barrage of survival 
signals from adipose tissue coterminous with potential sites of malignant disease. 
 Given the indisputable positive associations between obesity and breast cancer, 
it would follow that obesity reversal can achieve corresponding reversal of obesity-
associated cancer risk. However, the scientific community has failed to reach a 
consensus on the efficacy of weight loss on cancer risk and outcomes. Despite a 
handful of studies demonstrating intermediate reductions in biomarkers of cancer risk 
with intermittently promising outcomes, results are often inconsistent (14), thereby 
precluding an evidence-based recommendation of certain weight loss strategies for 
targeted breast cancer risk reduction. This is largely due to the low success rate of 
achieving significant weight loss and an even lower rate of long-term weight loss 
maintenance. Indeed, we and others have explored obesity-reversal in preclinical 
mouse models, and formerly-obese mice often exhibit persistent dysregulation in 
inflammation and adipose tissue homeostasis characteristic of obesity (15, 16). 
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 Although weight loss, in particular weight loss exclusively by low-fat diet, has not 
demonstrated success as a comprehensive risk reduction method, weight loss by 
bariatric surgery has shown auspicious results for reversal of obesity-associated tumor 
burden. Christou et al. showed that in comparison to morbidly obese control subjects, 
individuals who underwent bariatric surgery had a remarkable five-fold reduction in 5-
year incidence of all cancers and breast cancer (17). Bariatric surgery describes a 
variety of surgical procedures that modify the anatomy of the digestive tract in an effort 
to impart weight loss and resolve insulin resistance and hyperglycemia, for which it is 
often exceptionally effective. The two most common bariatric surgery procedures are 
Roux-en Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) (18). RYGB is 
regarded as the “gold standard” bariatric surgery procedure due to its extensive 
documented success in generating long-term weight loss and mitigation of obesity-
associated comorbidities. Until recently, RYGB was the most common bariatric 
operation, but due to the inherent complexity of constructing multiple anastomoses for 
each procedure and the associated surgical complications, VSG surpassed RYGB as 
the most common procedure in 2013, boasting a straightforward surgical protocol, low 
complication rate, and impressive clinical outcomes (19, 20). Weight loss achieved by 
VSG is comparable to RYGB, and both procedures give rise to greater weight loss and 
better hemoglobin A1c (HbA1c) outcomes, a diagnostic tool for diabetes, than standard 
medical therapy (21, 22). Furthermore, VSG does not pose a risk of vitamin and mineral 
absorption posed by RYGB, an important consideration for obese women of 
childbearing age (20). 
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A variety of mechanisms are under investigation to explain the efficacy of 
bariatric surgery with respect to endocrine health and cancer outcomes; top candidates 
include caloric restriction due to sensitive food reward signals, caloric malabsorption in 
the small intestine, gut hormone alterations, and bile acid and gut microbiota changes 
(18, 23). Furthermore, bariatric surgery has been shown to drastically modulate the 
epigenome, in particular DNA methylation. Studies have demonstrated profound 
remodeling of methylation profiles in gene clusters relevant to obesity caused by 
bariatric surgery. In one study comparing DNA methylation profiles in subcutaneous 
adipose tissue of women before and after undergoing bariatric surgery, researchers 
reported differential methylation in genes with established involvement in obesity-
associated adipose tissue dysfunction (24). Additional research has revealed that 
bariatric surgery can reverse obesity-associated DNA methylation signatures to levels 
comparable to never-obese subjects in skeletal muscle (25), and of particular 
importance to obesity-breast cancer link, adipose tissue (26). Given the potency of 
weight loss, metabolic improvements, and epigenetic modulation achieved exclusively 
by bariatric surgery, we sought to compare VSG and dietary weight loss as obesity-
reversal interventions and characterize their respective cancer-protective effects in a 
model of premenopausal basal-like breast cancer. 
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III. Hypothesis, Specific Aims 
Hypothesis: Considering the robust degree of longitudinal weight loss, endocrine 
health resolution, and epigenetic remodeling achieved by bariatric surgery, we 
hypothesize that weight loss by sleeve gastrectomy will generate sufficient metabolic 
normalization to reverse obesity-driven mammary tumor burden more effectively than 
weight loss by diet alone. 
 
Aim 1: Compare the effectiveness of bariatric surgery and weight loss by diet 
alone to reduce obesity-associated metabolic perturbations, adipose tissue 
dysfunction, inflammation, and tumor burden. 
 
Aim 2: Characterize the DNA methylation profiles in the mammary fat pad to 
determine exclusive regulation by weight loss intervention and test concordance 
with obesity-associated methylation in the Normal Breast Study. 
 
Aim 3: Profile the transcriptome of the mammary fat pad and conduct unbiased 
pathway analysis to identify key signaling pathways that are associated with 
favorable mammary tumor burden outcomes. 
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IV. Methods 
Animal Study Design: Husbandry and Diet 
All animal study protocols were approved and coordinated in compliance with guidelines 
issued by the University of North Carolina at Chapel Hill Institutional Care and Use 
Committee (IACUC). Ninety four female 6-8 week old C57BL/6 mice (a well 
characterized energy balance-responsive mouse model) were purchased from Charles 
River Laboratories International, Inc. (Wilmington, MA). Upon arrival, mice were housed 
two per cage on a 12-hour light/dark cycle and offered food and water ad libitum. A diet 
of standard chow was administered to all mice for a one week acclimation period. Next, 
mice were randomized to two groups, receiving either a control (CON; 10% kcal from 
fat) diet (n=22; Product # D12450J; Research Diets, Inc.) or a diet-induced obesity 
(DIO; 60% kcal from fat) regimen (n=72; Product # D12492; Research Diets, Inc.) to 
generate a normal-weight (NW) control or obese phenotype, respectively. Body weight 
and food intake were measured weekly. After 15 weeks on diet, with the weights of NW 
CON and DIO mice significantly different from each other (p<0.001), obese mice were 
then randomized to continue the DIO diet (Obese) or receive a surgical or diet weight 
loss intervention, resulting in formerly obese (FOB)-Surg and FOB-Diet groups, 
respectively. FOB-Surg mice were subject to sleeve gastrectomy (~80% excision of the 
stomach), and NW Control, Obese, and FOB-Diet mice received a sham procedure. 
Three days post-operation, both FOB-Surg and FOB-Diet began the same low-fat 
control diet as the NW Control group. Eight weeks after surgery when body weights of 
mice were relatively stabile, all mice were orthotopically injected with 3.5 x 104 E0771 
mammary tumor cells into the 4th mammary fat pad (Figure 1A), a model of basal-like 
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breast cancer originally isolated from a spontaneous medullary breast adenocarcinoma 
in a C57BL/6 mouse (27). In vivo tumor growth was measured two times per week with 
skinfold calipers and in vivo tumor area was determined using the formula πr2. Four 
weeks following orthotopic injection, tumors in 50% of Obese mice (the fastest growing 
group) reached the requisite size defined by the IACUC protocol; therefore, all mice on 
study were sacrificed. Mammary tumors, tumor-adjacent and tumor-distal mammary fat 
pad were excised and sectioned to either be formalin fixed or flash frozen in liquid 
nitrogen and stored at -80°C until further analysis. Ex vivo tumor volume was calculated 
using the formula 1/6π x D1 x D2 x D3 (where D is equal to ex vivo diameter of the 
tumor). End of study blood was collected by cardiac puncture, allowed to clot at room 
temperature for 30 minutes and centrifuged for 10 minutes at 1000 x g to isolate serum, 
and stored at -80°C.  
 
Sleeve Gastrectomy and Sham Procedures 
Sleeve gastrectomy and sham procedures were performed by trained animal surgeons 
according to a validated protocol (28). Briefly, vertical sleeve gastrectomy (VSG) 
involved excision of ~80% of the lateral stomach. The sham procedure, performed on 
NW Control, Obese, and FOB-Diet mice to control for the physiological insult of surgery, 
was executed by first isolating the stomach and then applying manual pressure with 
forceps for five seconds. The excision and pressure were applied along a line 
continuous with the esophagus and pylorus. All surgeries occurred within a four day 
window, and mice within all study groups were randomized to the day of operation. Pre-
operation fasting, exposure to isofluorane and administration of analgesics were 
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consistent across all groups. Additionally, all mice received a three-day liquid diet 
(Osmolite OneCal) before being reintroduced to solid food. Antibiotics were given to all 
mice three days post-op. All mice were weighed daily and food intake was quantified for 
one week post-op.  
 
Quantitative Magnetic Resonance Imaging Analysis 
Quantitative magnetic resonance imaging (qMRI) (Echo Medical Systems, Houston, TX) 
was used to measure the body composition for all groups (n=6-9 mice/group) at the end 
of study. Lean body mass, fat body mass, and free water were quantified. Body fat 
percentage was calculated by dividing the fat body mass by the body weight measured 
with a digital scale. 
 
Metabolic Analysis of Serum Hormones, Cytokines, and Adiponectin 
One week prior to tumor injection, serum was collected from mice fasted 4-6 hours by 
submandibular bleed. Serum hormones, cytokines, and adipokines including insulin, 
leptin, adiponectin, IL-6, TNFa, and resistin, were measured using Milliplex Mouse 
Metabolic Hormone Magnetic bead Panel (MMHMAG-44K), Bio-Plex ProTM Mouse 
Adiponectin Assay, and Mouse Cytokine Panel A 6- Plex, respectively (Bio-Rad 
Laboratories; Hercules, California). Insulin-like growth factor 1 (IGF- 1) concentrations 
were measured using R&D Systems IGF-1 Bead-Based Single-plex Luminex assay 
(Minneapolis, MN).  
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Mammary Fat Pad Adipocyte Size and Crown Like Structure Analysis 
Hematoxylin and eosin (H&E) staining on 4-micron thick sections from formalin-fixed, 
paraffin embedded distal mammary fat pad tissue was processed, scanned and imaged 
using Aperio CS2 Digital Pathology Scanner (Leica Biosystems, Wetzlar, Germany) at 
40X magnification. Representative snapshots (n=9-11 mice/group; 3 snapshots were 
sample) were randomly selected from whole tissue images zoomed in at 8.8X (300 μM) 
utilizing ImageScope Viewing Software Version 12.0 (Leica Biosystems). Mammary fat 
pad average adipocytes size and number of adipocytes were quantified using ImageJ 
Version 1.51e (National Institute of Health, Bethesda, Maryland). An adipocyte tool 
macro (MRI Adipocyte Tools.txt) was downloaded from 
(http://dev.mri.cnrs.fr/projects/imagej-macros/wiki/Adipocytes_Tool) and imported into 
ImageJ. Furthermore, the number of crown-like structures (CLS) (10) was quantified 
from whole tissue H&E stained distal mammary fat pad sections (n=10-15 mice/group). 
Briefly, the number of CLS were counted in a blinded fashion, and CLS density 
measures were achieved by dividing the number of CLS by the total slide area eligible 
for analysis using ImageScope Viewing Software Version 12.0 (Leica Biosystems).  
 
DNA methylation analysis 
Genome-wide methylation profiles for the distal mammary fat pad were determined by 
reduced representation bisulfite sequencing (RBBS). DNA was extracted from a random 
sample (n=4 mice/group) of distal mammary tissues using TRI Reagent (Sigma-Aldrich) 
according to the manufacturer's instructions. Library preparation and sequencing were 
performed at the University of North Carolina at Chapel Hill High-Throughput 
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Sequencing Facility. Alignment and differential methylation analysis were conducted as 
previously described (15). 
 
RNA-Seq 
Total RNA was extracted from the flash-frozen tumor-adjacent and tumor-distal 
mammary fat pad samples collected at the end of the study using TRI Reagent (Sigma-
Aldrich) according to the manufacturer's instructions. RNA libraries were prepared using 
the Illumina TruSeq Stranded Total RNA Sample Preparation kit according to 
manufactures instructions. The libraries were sequenced using a 2x76 bases paired end 
protocol on the Illumina HiSeq 2000 instrument. The reads were mapped to mouse 
genome (mm10) by TopHat (version 2.0.7). The number of fragments in each known 
gene from RefSeq database (UCSC Genome Browser 2013) was enumerated using 
HTSeq-count from HTSeq package (version 0.5.3p9). Differential expression was 
performed using DESeq2. 
 
Pathway Analysis 
WebGestalt (www.webgestalt.org) (29) over representation enrichment analysis (ORA) 
of KEGG pathways and gene ontology biological process curated gene sets was 
performed for selected pairwise comparisons of RNA-Seq and RRBS data.  
 
Statistical Analysis 
All values are represented as mean ± standard deviation (STDEV). One-way analysis of 
variance (ANOVA) using Tukey’s post hoc multiple comparisons correction was used to 
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assess the effects of diet and weight loss on body weight and fat percentage, tumor 
volume, serum hormone and cytokine concentrations, and mammary fat pad adipocyte 
size and CLS density. Results were analyzed using GraphPad Prism software 
(Graphpad Software Inc., La Jolla, CA) and p ≤ 0.05 was considered statistically 
significant.  
 
V. Results 
Weight Loss Interventions by Surgery (FOB-Surg) or Diet Alone (FOB-Diet) are 
Equally Effective at Reducing Body Weight and Fat Mass 
Mice were fed a low fat control or a diet-induced obesity regimen for 15 weeks in order 
to establish a normal weight control or obese phenotype, respectively. Obese mice had 
significantly higher body weight at the time of sleeve gastrectomy or sham procedure 
relative to control mice (p < 0.0001). Eight weeks following the operations and diet 
switch, body weight between FOB-Surg and FOB-Diet mice was not significantly 
different (Figure 1A), and neither group was significantly different from NW Control 
mice, however all were significantly different from Obese mice prior to tumor cell 
injection (p < 0.0001 for all comparisons, NW Control vs. Obese, FOB-Surg vs. Obese, 
FOB-Diet vs. Obese). At end of study, body fat percentage (Figure 1B) was not 
statistically different among NW Control, FOB-Surg and FOB-Diet mice, and all groups 
were significantly lower than Obese mice (p < 0.0001 for all comparisons, NW Control 
vs. Obese, FOB-Surg vs. Obese, FOB-Diet vs. Obese), indicating successful and 
equivalent reversal of the obese phenotype in both weight loss groups.  
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Figure 1. Surgical and dietary weight loss generate comparable reductions in body 
weight and body fat percentage. (A) Body weight of mice throughout the course of 
study. (B) Combined violin and box plots of body fat percentage at end of study. 
Differences in significance denoted by different letters (a,b) p-value <0.05.   
 
 
Surgical Weight Loss in Mice More Effectively Reduces Circulating Growth 
Factors and Pro-Inflammatory Mediators in Serum 
Seven weeks after surgical procedures and diet switch when weights were stabilized, 
serum was collected from mice (n=10-12 mice/group) by submandibular bleed for 
multiplex metabolite analyses. For all metabolites measured except adiponectin, levels 
in NW Control mice were significantly lower than Obese mice. Insulin levels in FOB-
Surg mice were significantly different from both FOB-Diet and Obese mice and not 
significantly different from NW Control mice; insulin levels in FOB-Diet exhibited 
intermediate reductions from Obese levels but were not significantly different. For 
Insulin-like growth factor-1 (IGF-1) and resistin, FOB-Surg mice displayed significantly 
lower levels than Obese mice, whereas FOB-Diet mice displayed intermediate, non-
significant reductions from Obese levels. For measures of leptin, leptin to adiponectin 
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ratio, interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1), both FOB-
Surg and FOB-Diet mice displayed significantly lower levels relative to Obese mice. 
Lastly, FOB-Surg mice exhibited significantly lower levels of tumor necrosis factor alpha 
(TNFa) than both FOB-Diet and Obese mice; levels of TNFa in FOB-Diet mice were not 
statistically different from only Obese mice (Table 1).  
 
 
 
 
 
 
 
 
NW Control FOB-Surg FOB-Diet Obese
Insulin (ng/mL) 0.74 ± 0.25a,b 0.56 ± 0.22a 1.04 ± 0.35b,c 1.35 ± 0.49c
IGF-1 (ng/mL) 42.2 ± 13.8a 39.0 ± 15.9a 51.4 ± 18.6a,b 76.7 ± 29.6b
Leptin (ng/mL) 2.41 ± 0.89a 2.16 ± 1.20a 4.77 ± 4.21a 11.5 ± 0.05b
Adiponectin (µg/mL) 12.0 ± 2.99 11.1 ± 5.01 12.6 ± 2.91 9.68 ± 5.13
Leptin:Adiponectin 2.22E-06 ± 1.34E-06a 2.34E-06 ± 1.29E-06a 4.95E-06 ± 5.29E-06a 3.50E-05 ± 1.30E-05b
Resistin (ng/mL) 11840 ± 4143a 6732 ± 2237a 12528 ± 4717a,b 20214 ± 10323b
TNF! (pg/mL) 11.5 ± 7.31a 18.8 ± 14.1a 41.2 ± 14.1b 56.9 ± 18.2b
IL-6 (pg/mL) 30.6 ± 8.21a 39.5 ± 17.5a 50.8 ± 24.0a 89.4 ± 20.6b
MCP-1 (pg/mL) 99.8 ± 5.34a 102.2 ± 22.4a 136.8 ± 50.4a 192.3 ± 51.9b
Cytokines
Hormones
Table 1.     Serum hormones and cytokines
Data presented as mean ± std dev. One-way ANOVA and Tukey's post hoc multiple comparisons were used to test statistical differences 
between study groups. Results from pairwise comparisons are presented as letters, where common letters indicate statistical equivalence and 
different letters indicate statistical difference according to p<0.05.
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Surgical Weight Loss in Mice Reverses Adipocyte Hypertrophy and Crown-Like 
Structure Density in the Mammary Tissue 
Adipocyte area in the mammary fat pad displayed significant fluctuation by phenotype. 
Both surgical and dietary weight loss resulted in reduced adipocyte area, with the most 
profound differences relative to Obese mice occurring at the 50th and 90th percentile of 
adipocyte area (Figure 2A). More precisely, FOB-Surg mice exhibited an average 
adipocyte area not significantly different from NW Control mice and significantly different 
from both FOB-Diet and Obese Mice (p<0.0001), while average adipocyte area of FOB-
Diet mice displayed significant reduction relative to Obese mice (p<0.0001) but 
remained significantly different from both NW Control (p<0.0001) and FOB-Surg 
(p<0.05) (Figure 2B). Furthermore, density of crown-like structures in the mammary fat 
pad was lowest in FOB-Surg mice and significantly lower than that of FOB-Diet and 
Obese mice. Of note, crown-like structure density in FOB-Diet mice was not statistically 
different from Obese mice (Figure 2C). Representative images of H&E stained 
mammary fat pad depicting adipocyte size and CLS are displayed (Figure 2D). 
 
Surgical Weight Loss, but not Weight Loss by Diet Alone, Reverses the Pro-
Tumorigenic Effects of Obesity  
Intriguingly, ex vivo tumor volume of FOB-Surg mice was not statistically different 
fromNW Control mice and significantly different than Obese mice. However, FOB-Diet 
mice had tumors that were not significantly different from Obese mice and significantly 
different than NW Control mice (Figure 3). Therefore, FOB-Surg mice, but not FOB-Diet 
mice, achieved reversal of obesity-associated mammary tumor burden. 
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Figure 2. Surgical weight loss results in more robust reductions in adipocyte 
hypertrophy and crown-like structure density in the mammary fat pad. (A) Panel 
displaying density functions for 10th, 50th, and 90th percentiles of adipocyte area across 
all groups; dashed red line indicates mean of distribution. (B) Average adipocyte area. 
(C) Crown-like structure density. (D) Representative images of H&E stained mammary 
fat pad sections depicting adipocyte size and CLS. Differences in significance denoted 
by different letters (a,b,c) p-value <0.05.   
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Figure 3. Ex vivo tumor volume reveals unique cancer-protective effects of surgical 
versus dietary weight loss. Differences in significance denoted by different letters (a,b,c) 
p-value <0.05.   
 
 
The Methylation of Genes in the Mammary Tissue of Mice that Lost Weight via 
Surgery Displays a Pattern that is Distinct from FOB-Diet and Obese mice  
The complete RRBS dataset was filtered by pairwise comparisons between all study 
groups with p<0.0001 and false discovery rate (FDR)<0.0001 as filtering criteria for 
differential methylation. Genes with differential methylation according to these criteria at 
any gene feature (e.g. promoter, intron) were included. Gene lists were entered into 
WebGestalt for overrepresentation enrichment analysis (ORA) in curated KEGG 
pathways (Table 2). The genes harboring differential methylation between Obese and 
FOB-Surg mice were highly enriched for a variety of pathways implicated in mammary 
carcinogenesis and a tumorigenic microenvironment. Interestingly, there were markedly 
fewer genes displaying differential methylation according to the criteria above in Obese 
vs. FOB-Diet mice relative to Obese vs. FOB-Surg mice (2011 and 4258 genes, 
respectively), suggesting that Obese mice have a global DNA methylation profile more 
similar to FOB-Diet mice than FOB-Surg mice. Lastly, there was considerable 
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redundancy in pathways represented by differentially methylated genes between FOB-
Diet vs FOB-Surg mice and Obese vs FOB-Surg mice, suggesting that Obese and 
FOB-Diet mice share a significant number of similar DNA methylation features that 
explain overlapping pathway enrichment relative to FOB-Surg mice. 
 
The Expression of Genes in the Mammary Tissue of Mice that Lost Weight via 
Surgery Displays a Pattern that is Distinct from FOB-Diet and Obese mice  
RNA Sequencing data was filtered to create gene lists for all pairwise comparisons 
between groups; differential expression with group-specific directionality was achieved 
by selecting genes with log2(fold change) > 0.58 (which is equivalent to fold change > 
1.5) for each inter-group comparison. Gene lists were entered into WebGestalt for 
overrepresentation enrichment analysis (ORA) in curated KEGG pathways. There was 
significant overlap between pathways upregulated in Obese vs. FOB-Surg mice and 
FOB-Diet vs FOB-Surg mice, pointing to critical gene clusters that display robust  
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activation by obesity and persist despite weight loss by diet alone (Figure 4A,B). These 
pathways are well-characterized in the context of obesity and breast cancer risk and 
suggest broad activation of canonical cell signaling cascades involved in cell 
proliferation, growth, and extracellular matrix function. Next, comparisons of the two 
weight loss groups to Obese mice reveals significant overlap in pathway 
characterization reflecting upregulated genes in FOB-Surg (Figure 4C) and FOB-Diet 
(Figure 4E) mice vs. Obese mice. There were remarkably few upregulated genes in 
Obese vs. FOB-Diet mice relative to other comparisons. The resulting ORA revealed a 
Observed Genes 
in Pathway
Percent of All 
Genes in Pathway P-value FDR
Signaling pathways regulating pluripotency of stem cells* 47 33.6 1.34E-07 2.00E-05
Breast cancer* 47 32.4 4.36E-07 3.75E-05
Pathways in cancer* 99 25.3 5.02E-07 3.75E-05
Basal cell carcinoma* 22 1.36E-05 8.13E-04
Rap1 signaling pathway 56 26.5 3.76E-05 1.87E-03
Insulin secretion* 27 33.3 7.21E-05 2.57E-03
Ras signaling pathway 58 25.7 7.74E-05 2.57E-03
Wnt signaling pathway 41 28.1 1.07E-04 2.92E-03
Hippo signaling pathway* 42 27.3 1.82E-04 4.31E-03
Focal adhesion* 51 25.1 3.61E-04 6.75E-03
Differentially methylated Obese vs FOB-Diet (n = 2011)
Insulin secretion* 18 22.2 5.39E-05 6.38E-03
Breast cancer* 26 17.9 7.09E-05 6.38E-03
Pathways in cancer* 53 13.5 8.53E-05 6.38E-03
Signaling pathways regulating pluripotency of stem cells* 20 14.3 6.26E-06 1.87E-03
Focal adhesion* 23 11.3 6.12E-05 5.15E-03
Hippo signaling pathway* 19 12.3 8.62E-05 5.15E-03
Breast cancer* 18 12.4 1.22E-04 6.08E-03
Basal cell carcinoma* 10 18.2 1.86E-04 7.94E-03
Respective	gene	sets	were	subjected	to	over	representation	enrichment	analysis	(ORA)	for	specific	KEGG	pathways	as	compared	to	the	mouse	
genome	by	applying	a	hypergeometric	test	and	threshold	minimum	of	five	genes	represented	in	the	pathway.	Asterisk	indicates	redundant	
pathway	among	the	comparisons.	FDR:	false	discovery	rate.	
Table 2.     KEGG pathways enriched for differentially methylated genes
Differentially methylated Obese vs FOB-Surg (n = 4258)
Pathway
Differentially methylated FOB-Surg vs FOB-Diet (n = 1107)
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correspondingly small number of enriched pathways (Figure 4D), perhaps telling of 
latent obesity-associated gene expression patters in FOB-Diet but not FOB-Surg mice. 
Lastly, the genes that were upregulated in FOB-Surg vs. FOB-Diet mice were enriched 
for pathways implicated in a spectrum of inflammatory processes (Figure 4F). 
Considering the potential inconsistencies between this pathway analysis and the serum 
metabolite data in Table 1 showing FOB-Surg mice having lower levels of inflammatory 
markers relative to FOB-Diet mice, gene-level analyses were pursued. 
Interestingly, explorations of redundant pathways upregulated in both FOB-Diet and 
FOB-Surg mice revealed group-exclusive expression profiles of distinct molecular 
functions. For example, the “Cytokine-cytokine receptor interaction” KEGG pathway was 
shown to be enriched for genes upregulated in FOB-Diet vs. FOB-Surg mice and vice 
versa. In this pathway, Lep, the gene encoding the adipokine leptin, was upregulated in 
FOB-Diet vs.FOB-Surg mice, whereas Lepr, the gene encoding leptin receptor, was 
upregulated in FOB-Surg vs. FOB-Diet mice, perhaps suggesting resolution of leptin 
resistance. The proinflammatory chemokine Ccl7 and chemokine receptor Ccr1 (30) 
were both upregulated in FOB-Diet vs. FOB-Surg, and the anti-inflammatory cytokine 
interleukin-10 receptor Il10ra (31) and anti-obesigenic chemokine Cxcr4 (32) were both 
upregulated in FOB-Surg vs. FOB-Diet.  
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Figure 4. Pathway analysis of differentially expressed genes in the mammary fat pad. 
Selected KEGG pathways showing enrichment for differentially expressed (fold change 
> 1.5) genes with corresponding p-values from hypergeometric test for 
overrepresentation enrichment analysis (ORA). Pathways displayed for genes (A) 
upregulated in Obese vs FOB-Surg mice, (B) upregulated in FOB-Surg vs Obese mice, 
(C) upregulated in FOB-Diet vs FOB-Surg mice, (D) upregulated in Obese vs FOB-Diet 
mice, (E) upregulated in FOB-Surg vs FOB-Diet mice, and (F) upregulated in FOB-Diet 
vs Obese mice. 
 
DNA Methylation and Gene Expression Profiles of Genes Altered After Surgical 
Weight Loss Displays Partial Concordance with Human Data Sets 
Genes exhibiting significant hyper- and hypomethylation in Obese vs NW Control, FOB-
Surg, or FOB-Diet mice were selected by calculating the difference in average percent 
methylation of the groups and attributing significance according to false discovery rate < 
0.05 and p-value < 0.05. These differentially methylated features were compared to 
DNA methylation data obtained from mammary tissue cataloged in the Normal Breast 
Study showing concordant hyper- or hypomethylation in obese subjects. Displayed are 
results of concordance analysis (Table 3) showing robust alignment of genes implicated 
in a variety of pathways relevant to carcinogenesis and regulation of cell proliferation. 
Additionally, gene ontology (GO) and KEGG pathways regulated by differential gene 
expression were compared to a microarray gene expression study of white adipose 
tissue (WAT) of obese vs. lean subjects and subjects after vs. before undergoing 
bariatric surgery performed by Henegar et al. (33). For concordance analysis, Obese vs. 
NW Control mice were used in comparison with obese vs. lean subjects. Our data 
exhibited overlap in up- and down-regulated pathways, with six out of eleven GO and 
five out of ten KEGG pathways showing identical regulation for comparisons between 
obese vs. lean subjects and Obese vs. NW Control mice. Furthermore, Obese vs. FOB-
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Surg mice were used in comparison with analysis of samples after vs. before bariatric 
surgery. Again, our data displayed unique similarity with directional regulation of GO 
and KEGG pathways, with eight out of fourteen GO and five out of 12 KEGG pathways 
showing identical regulation. 
 
 
VI. Discussion 
 The results of our preclinical study using a mouse model of premenopausal 
basal-like breast cancer demonstrate that weight loss by bariatric surgery, but not 
weight loss by diet alone, is able to reverse obesity-driven transformations in 
metabolism, inflammation, DNA methylation, gene expression, and mammary tumor 
burden. Consistent with established trends in the literature, Obese mice, relative to NW 
Control mice, exhibited significantly higher levels of the following obesity-associated 
cancer promoting perturbations: serum hormones (insulin, IGF-1, leptin:adiponectin, 
resistin), circulating inflammatory markers (TNF-a, IL-6, MCP-1), body weight, body fat 
percentage, adipocyte size, and CLS density in the mammary fat pad. FOB-Surg mice, 
which achieved an obese phenotype by consuming a high fat diet for 15 weeks and 
underwent a vertical sleeve gastrectomy procedure followed by a switch to a low fat 
diet, displayed significant reductions in the obesity-associated cancer promoting 
perturbations from Obese mice and not significantly different from NW Control mice in 
all of these measures. FOB-Diet mice, which likewise achieved an obese phenotype 
and received a sham procedure followed by a switch to a low-fat diet to lose weight, 
displayed significant reductions from Obese mice in measures of body weight, body  
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percentage, leptin:adiponectin, IL-6, and MCP-1, although mammary adipocyte size 
remained significantly higher than NW Control mice. FOB-Surg mice, but not FOB-Diet 
mice, exhibited average adipocyte size, CLS density, circulating TNF-a, and ex vivo 
mammary tumor volume was not significantly different from NW Control mice, while the 
same measures in FOB-Diet mice, (with the exception of adipocyte size, which was 
intermediate), were not significantly different from Obese mice. Therefore, we conclude 
that surgical weight loss imparted a plurality of metabolic advantages and successful 
reversal of obesity-associated mammary tumor burden that were not similarly achieved 
by dietary weight loss.  
 In order to provide a comprehensive molecular comparison of surgical and 
dietary weight loss relevant to breast cancer risk and progression, we performed parallel 
mRNA sequencing and reduced representation bisulfite sequencing of the mammary fat 
pad to delineate functional changes in the transcriptome and epigenome. Intriguingly, 
there were many more genes with differentially methylated features in Obese vs. FOB-
Surg mice (n=4258 genes) than Obese vs. FOB-Diet mice (n=2011 genes), suggesting 
that surgical weight loss was more effective at generating a DNA methylation profile 
distinct from Obese mice. Differentially methylated genes in Obese vs. FOB-Surg mice 
and FOB-Diet vs. FOB-Surg mice were enriched for similar canonical signaling 
pathways, pointing to DNA methylation as a potential mechanism by which obesity-
driven cellular changes remain active in FOB-Diet mice but not FOB-Surg mice.   
 Next, differentially expressed genes were subjected to unbiased pathway 
analysis to highlight coherent gene clusters in the context of curated signaling 
pathways. Similar to trends observed in pathway analysis of differentially methylated 
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genes, pathways upregulated in Obese vs. FOB-Surg mice and FOB-Diet vs. FOB-Surg 
mice exhibited substantial redundancy, suggesting that obesity-associated gene 
expression profiles in the mammary fat pad are responsible for characterizing 
differential gene expression between mice that underwent dietary vs. surgical weight 
loss. Genes and pathways that were upregulated by the weight loss interventions (that 
is, upregulated genes and pathways in FOB-Diet vs. Obese mice and FOB-Surg vs. 
Obese mice) showed considerable similarity in their biological function. Namely, the 
majority of the pathways involved macronutrient metabolism and metabolic machinery 
of core anabolic and catabolic pathways, such as fatty acid metabolism, tricarboxylic 
acid (TCA) cycle, insulin signaling, pyruvate metabolism, and peroxisome proliferator-
activated receptor (PPAR) signaling. These results provide robust evidence for the 
centrality of metabolic control in obesity-reversal interventions. Interestingly, genes 
upregulated in FOB-Surg vs. FOB-Diet mice are heavily enriched for pathways 
implicated in a variety of inflammatory processes, despite powerful anti-inflammatory 
effects of surgical weight loss substantiated by circulating cytokine levels and CLS 
density in the mammary fat pad. However, curated signaling pathways often assemble 
genes that both positively and negatively regulate a given process under a common 
term. Therefore, further gene-level analysis is warranted to understand the distinct 
molecular mechanisms of inflammation that are regulated by the two weight loss 
interventions respectively.  
 Lastly, the sequencing results of our animal study demonstrate considerable 
similarity with similar molecular investigations in humans. The results of our RRBS 
studies were compared to DNA methylation in normal breast tissue from the Normal 
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Breast Study. This study generated correlation coefficients between methylation levels 
and obesity, and accordingly each methylation probe can be observed for up- or 
downregulation in obesity. Concordance analysis between these two datasets revealed 
a number of gene features that exhibit concordant reduction or enrichment of CpG 
methylation in obese vs. nonobese women in comparions to Obese vs. NW Control 
mice, Obese vs. FOB-Surg mice, and failure to reverse these trends in FOB-Diet mice. 
The resulting genes are therefore critical targets under epigenetic control that in part 
mediate the differential outcomes between the two weight loss groups.  
 This is the first study to compare the effects of surgical vs. dietary weight loss on 
mammary tumor burden in a preclinical mouse model of basal-like breast cancer. In 
light of a recent study by our group that discovered persistent obesity-associated 
inflammation, DNA methylation, and tumor outcomes in formerly-obese mice that lost 
weight by diet (15), we report that similar obesity-associated measures are successfully 
reversed via weight loss by sleeve gastrectomy alone. Leveraging the power of next-
generation sequencing platforms, RNA-Seq revealed upregulation of macronutrient 
metabolic machinery as a consistent transcriptomic phenomenon between both weight 
loss groups. However, we observed an upregulation of certain molecular processes 
implicated in the innate immune and inflammatory response in FOB-Surg mice 
compared to FOB-Diet, which are perhaps at play in the exclusive cancer-protective 
effects observed in FOB-Surg mice. Lastly, genome-wide DNA methylation profiles are 
distinct between the two weight loss groups, highlighting the importance of epigenetic 
reprogramming in response to ambient nutrient load and whole-organism physiology. 
Further studies combining dietary weight loss and targeted inhibition of gene products 
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with persistent obesity-associated expression are needed to obviate the burden of 
undergoing bariatric surgery while mimicking the procedure’s unique cancer-protective 
effects. 
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